Regeneron stumbles in PhI Libtayo combo study as safety concerns force suspension
Faced with unexpected safety concerns, Regeneron has slammed the brakes on a Phase I study testing a combination of its PD-1 drug Libtayo and an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
